CellGene Biotech Flow Cytometry Reagents Used in Published Plasma p-tau217 Alzheimer's Study

A newly published study in Springer Nature's Journal "Translational Psychiatry" evaluated multiple plasma p-tau217 assay platforms for Alzheimer's disease, including a cytometric bead array assay manufactured by CellGene Biotech.

The study demonstrated that the CellGene Biotech flow cytometry-based CBA assay successfully measured plasma p-tau217 and differentiated Alzheimer's disease dementia from cognitively unimpaired controls and non-AD dementia groups. The assay also showed significant concordance with the established ALZpath Simoa reference assay.

In the Alzheimer's disease dementia versus control comparison, the CellGene Biotech CBA assay achieved:

* 100% specificity

* 88.9% sensitivity

* 92.2% overall accuracy

Unlike platforms that require dedicated single-molecule or digital immunoassay instruments, the CellGene Biotech assay is designed for flow cytometry-based detection. This provides laboratories with a practical route to Alzheimer's biomarker research using familiar cytometry workflows and existing flow cytometry infrastructure.

CellGene Biotech's plasma p-tau217 flow cytometry reagent kit offers a differentiated solution for Alzheimer's disease biomarker testing, supporting research hospitals, clinical laboratories, CROs, and translational research groups interested in blood-based neurodegenerative disease biomarkers.

To our knowledge, CellGene Biotech currently provides the only flow cytometry-based Alzheimer's diagnostic reagent kit for plasma p-tau217 detection.

（Please click the attachment to view the original article.）